Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT ID: NCT07743450
Registry status: Recruiting
Study type: Not specified in the registry data
Phase: Phase 3
Sponsor: Ascletis Pharma (China) Co., Limited

Overview

ClinicalTrials.gov lists this study as Recruiting.

Enrollment: 1560 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages: Not specified in the registry data
Sex: Not specified in the registry data
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: 1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening. 2. Have a BMI ≥ 27 kg/m2 at screening. 3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. 4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c \> 6.5% (48 mmol/mol) to ≤10.5% (91 mmol/mol) at screening. Exclusion Criteria: 1. Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM. 2. Have a self-reported change in body weight \>5 kg (11 pounds) within 3 months prior to screening. 3. Have an estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73 m2, as determined by the laboratory at screening. 4. Have a history of acute or chronic pancreatitis any time prior to screening. 5. Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA). 6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2. 7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study at the investigator's discretion.

Study locations

118 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Czechia, Germany, Greece, Poland, United Kingdom, United States

Alabama, United States: 2
Arizona, United States: 3
Arkansas, United States: 1
California, United States: 9
District of Columbia, United States: 1
Florida, United States: 9
Georgia, United States: 3
Idaho, United States: 1
Illinois, United States: 1
Indiana, United States: 3
Kansas, United States: 1
Louisiana, United States: 2
Maryland, United States: 2
Michigan, United States: 1
Minnesota, United States: 1
Mississippi, United States: 3
Missouri, United States: 2
Nevada, United States: 1
New Jersey, United States: 1
New York, United States: 3
North Carolina, United States: 5
Ohio, United States: 4
Oklahoma, United States: 1
Oregon, United States: 1
Pennsylvania, United States: 2
South Carolina, United States: 4
Tennessee, United States: 1
Texas, United States: 12
Utah, United States: 1
Virginia, United States: 1

Sample of listed locations

AURORA-2 Clinical Site — Pardubice, 530 02, Czechia — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Prague, 120 00, Czechia — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Uherské Hradiště, 686 01, Czechia — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Berlin, 10629, Germany — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Essen, 45355, Germany — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Hanover, 30159, Germany — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Athens, 106 76, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Larissa, 411 10, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Marousi, 151 23, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Palaió Fáliro, 175 62, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Pylaia, 570 01, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Thessaloniki, 546 36, Greece — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Biała Podlaska, 21-500, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Bydgoszcz, 85-092, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Częstochowa, 42-202, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Gdansk, 80-382, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Gdynia, 81-384, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Katowice, 40-040, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Krakow, 31-261, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Lodz, 90-127, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Lublin, 20-011, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Poznan, 60-324, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Puławy, 24-100, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Siedlce, 08-110, Poland — Site recruitment status not specified in the registry data
AURORA-2 Clinical Site — Staszów, 28-200, Poland — Site recruitment status not specified in the registry data

Study details

Start date: August 28, 2026
Primary completion date: July 1, 2028
First posted: August 3, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07743450
Registry last updated: September 16, 2026
QualifiedStudies registry data refreshed: September 21, 2026

View NCT07743450 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ